Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
C. H. van Dyck, M.D. May 3, 2017 CURRICULUM VITAE Christopher H. van Dyck, M.D. Home Address: Home Phone: KS 376 Sperry Road, Bethany, CT 06524 (203) 393-2215 Office Address: Alzheimer’s Disease Research Unit Yale University School of Medicine One Church Street, Suite 600 New Haven, CT 06510 Email Address: Website: Office Phone: Office Fax: [email protected] http://www.alzheimers.yale.edu (203) 764-8100 (203) 764-8111 Birth Date: 8/25/55 Birth Place: Wichita, Education: BA MD Yale College, 1978 (cum laude) Northwestern University Medical School, 1984 Career: 1984-1985 1985-1988 1988-1990 1990-1991 1991-1992 1992-1997 1988-Present 1990-Present 1992-Present 1997-2007 2002-2007 Internship in Internal Medicine, Norwalk Hospital, Norwalk, CT Residency in Psychiatry, Yale University School of Medicine, New Haven, CT Fellowship in Geriatric Psychiatry, Yale University School of Medicine, New Haven, CT Research Fellowship, Department of Psychiatry, Yale University School of Medicine, New Haven, CT Associate Research Scientist, Department of Psychiatry, Yale University School of Medicine, New Haven, CT Assistant Professor of Psychiatry, Yale University School of Medicine, New Haven, CT Consultant in Geriatric Psychiatry, Adler Geriatric Assessment Center, Yale New Haven Hospital, New Haven, CT Attending, Yale New Haven Hospital, New Haven, CT Director, Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT Associate Professor of Psychiatry, Yale University School of Medicine, New Haven, CT Associate Professor of Neurobiology (Secondary Appointment), Yale University School of Medicine, New Haven, CT 1 C. H. van Dyck, M.D. 2006-Present 2007-Present May 3, 2017 Director, Division of Aging and Geriatric Psychiatry, Department of Psychiatry, Yale University School of Medicine Professor of Psychiatry and Neurobiology, Yale University School of Medicine, New Haven, CT Licensure: Connecticut License #027403 National Provider Identifier (NPI) 1821088188 Board Certification: American Board of Psychiatry and Neurology: Psychiatry (October 1991) Certificate #34888 Added Qualifications in Geriatric Psychiatry (April 1994, 2005) Certificate #1242 Professional Honors or Recognition: 1973 1978 1983 1984 1995 1996 1997-Present 2000 2001 2004 2004 2005-Present 2005 2006 2009 National Merit Scholarship Departmental Distinction in the Major (Philosophy), Yale University Rock Sleyster Memorial Scholarship in Psychiatry Paolo Raimondi Memorial Award for Humanism in Medicine, Northwestern University American Federation for Aging Research (AFAR) Grant Award Junior Investigator Award, American Association for Geriatric Psychiatry Top Doctors: New York Metro Area, Selected by Castle Connolly Medical, Ltd. NARSAD Independent Investigator Award Alzheimer’s Association Investigator-Initiated Research Grant Award American Health Assistance Foundation Research Grant Award Ethel F. Donaghue Women’s Health Investigator Award Best Doctors in New York (Top 2%), as Featured in New York Magazine “Compassion and Cure” Award, Alzheimer’s Association Top 10 articles in Neuropsychopharmacology of 2006 (at ACNP meeting; Zdanys et al, 2007) Honorary Master of Arts Privatim degree, Yale University Departmental, Medical School, and University Committees: 1995-Present 1996-1998 1997-Present 1997-Present Departmental Task Force for Geriatric Psychiatry Quality Assurance, Yale New Haven Hospital (Psychiatry Department Representative Executive Committee, Neurochemical Brain Imaging Program, Yale University School of Medicine. Fellow, Calhoun College, Yale University. 2 C. H. van Dyck, M.D. 1998-2000 2002-2003 2003-2005 2007 May 3, 2017 Credentials Committee, Yale New Haven Hospital Departmental Task Force for Research Protocol Review Yale-Pfizer Joint Science Committee Yale Human Investigation Committee, Policy Meeting “Considerations for involving permanently or transiently decisionally impaired subjects in research.” Other Professional Activities: Memberships: Society for Neuroscience Society of Nuclear Medicine International Society for Neuroimaging in Psychiatry American Association for Geriatric Psychiatry; Research Committee; Member in Training Award Committee; Early Career Scientist Award Committee; Distinguished Scientist Award Committee (Chairman 2009-2010). American Psychiatric Association Connecticut Psychiatric Society; member, Geriatric Psychiatry Committee Editorial Boards, Journal Referees, Grant Reviews: 2000-Present 2004-Present 2007-Present 2007-Present 2007-Present 2010- Editorial Board, Journal of Nuclear Medicine. Editorial Board, Current Medical Imaging Reviews (Bentham Sciences). Editorial Board, Brain Imaging and Behavior (Springer). Editorial Board, The Open Medical Imaging Journal (Bentham Sciences). [6/1/10: still active*] Editorial Board, The Open Neuroimaging Journal (Bentham Sciences). [6/1/10: still active*] Editorial Board (Associate Editor), Journal of Alzheimer's Disease Journal Referee for Journal of Nuclear Medicine, Journal of Cerebral Blood Flow and Metabolism, Psychiatry Research: Neuroimaging, Journal of Neuroscience, Neuroscience Letters, Biological Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Life Sciences, Magnetic Resonance Imaging, American Journal of Geriatric Psychiatry, and Current Medical Imaging Reviews. Abstract Reviewer for: American Association for Geriatric Psychiatry Annual Meeting, Brain’05 and BrainPET’05, June 7-11, 2005, Vrije Universiteit, Amsterdam. 2002-Present Research Grant Reviewer for Alzheimer’s Association 3 C. H. van Dyck, M.D. 2003-Present May 3, 2017 Grant Reviewer for National Institute of Health, Center for Scientific Review, Brain Disorders and Clinical Neurosciences ZRG1 BDCN-2 (02), William C Benzing, Ph.D., SRA. INDs Sponsored: 2001-2010: 2001-Present: IND #61,156, “Evaluation of [I-123]5-I-A-85380 as a SPECT Tracer to Image Nicotinic Acetylcholine Receptors in Brain.” “IND #42,798, “Evaluation of [123I](1R)-ß-CIT as a SPECT Marker of Striatal Monoaminergic Innervation.” Consulting / Scientific Advisory Boards 1988-Present 1990-2003 2000-2003 1995-Present 1996-1998 2000-2001 1997-2001 2001-2002 2/23-25/03 2003-2008 2003-2005 Consultant in Geriatric Psychiatry, Adler Geriatric Assessment Center, Yale New Haven Hospital, New Haven, CT Consultant in Geriatric Psychiatry, Bentley Gardens Health Care Ctr, West Haven, CT Consultant in Geriatric Psychiatry, Soundview Convalescent Home, West Haven, CT Legal Consultant (to various attorneys) regarding decision making capacity in Alzheimer’s disease and related disorders, and regarding risk factors for developing Alzheimer’s disease and related disorders Scientific Advisory Board, Mediolanum Pharmaceuticals (regarding SPECT imaging studies in Alzheimer’s disease) Consultant to Pfizer, Inc for staff training in Alzheimer’s disease Designed, organized, and presented training preceptorships (primarily for marketing staff) in the basic neurobiology, clinical presentation/evaluation, and pharmacological treatment of Alzheimer’s disease. Consultant to SCIREX Corporation (CRO) regarding Alzheimer’s disease clinical trials Evaluated sponsor FDA protocols. Assisted in preparation and presentation of proposals for CRO conduct of protocols. Served as consultant and medical monitor during conduct of Alzheimer’s disease clinical trials. Provided staff training and education in Alzheimer’s disease for staff of CRO and sponsoring pharmaceutical companies. Presented at Investigator Meetings. Consultant to Biovail Corporation regarding Alzheimer’s disease clinical trials Evaluated preclinical literature and sponsor FDA protocols. Attended meetings with sponsor. Invited Participant, Janssen CNS Advisory Summit, Scottsdale AZ. Scientific Advisory Board, Forest Laboratories. Consultant, Pilot Collaborative PET Imaging Trial (5 R01 AG022394-02, P.I. Norman Foster, University of Michigan Health System). 4 C. H. van Dyck, M.D. 2005-Present 2008-Present 2009-Present 2010-Present 2010-Present May 3, 2017 Expert for the NIH Genetic Association Database (http://geneticassociationdb.nih.gov) for: ApoE4 and Alzheimer’s Disease; Dopamine Transporter (SLC6A3); Serotonin Transporter (SLC6A4) Scientific Advisory Board, Bristol-Myers Squibb (regarding Alzheimer’s disease and clinical trial design) Scientific Advisory Board, GlaxoSmithKline (regarding Alzheimer’s disease and FDA clinical study report) Scientific Advisory Board, Pfizer, Inc and Janssen Immunotherapy (regarding Alzheimer’s disease anti-amyloid therapeutics and vasogenic edema) Scientific Advisory Board, Elan Pharmaceuticals (regarding Alzheimer’s disease and investigational therapeutic agent) Speakers Bureaus: 2000-2003 2000-2002 2002-2004 2003-2005 Pfizer Pharmaceuticals Novartis Pharmaceuticals Janssen Pharmaceuticals Forest Laboratories Lectures, Courses: 10/27/93 11/14/93 1/28/94 1994-1996 6/7/94 12/14/94 1995-1997 4/4/95 6/26/96 7/17/96 Invited Speaker, Alzheimer's Association, South Central Connecticut Chapter Invited Speaker, Alzheimer's Association, South Central Connecticut Chapter: “New Treatments for Alzheimer's Disease.” Stratford, CT. Presenter, Research Forum, Department of Psychiatry, Yale University School of Medicine Guest Lecturer, Shoals Marine Laboratory (Cornell University), Appledore, Maine (Neurobiology of Animal Behavior) Invited Speaker, Society of Nuclear Medicine, Technologists Section:“SPECT Imaging of Alzheimer's Disease.” Orlando, FL. Invited Speaker, Yale Program on Aging and Claude D. Pepper Older Americans Independence Center: “Imaging the Aging Dopamine System with SPECT.” Lecturer, Geriatric Resource Nurse Program Conference, Yale University School of Nursing Invited Speaker, Geriatric Seminar Series, Department of Psychiatry, The New York-Cornell Medical Center, Westchester Division: “SPECT Imaging in Normal Aging and Alzheimer's Disease.” Invited Speaker, Alzheimer's Association, Southern Connecticut Chapter: “Genetics of Alzheimer's Disease.” Invited Speaker, Southern Connecticut State University: “New Developments in Alzheimer's Disease.” 5 C. H. van Dyck, M.D. 3/3/97 3/18/98 4/20/98 10/16/98 5/7/99 2/19/00 3/2/00 3/13/00 3/15/00 4/13/00 4/24/00 4/28/00 9/5/00 9/14/00 10/12/00 May 3, 2017 Symposium Speaker and Chairman, American Association for Geriatric Psychiatry: “Imaging the Aging Dopamine System.” (educational symposium for annual meeting of AAGP) Invited Speaker, Connecticut Psychiatric Society Resident’s Day, Berlin CT: “Topics in Alzheimer's Disease: Clinical Genetics and Current Treatments.” Invited Speaker, 1998 Neuroscience Symposium on “Aging,” sponsored by The Western North Carolina Chapter of the Society for Neuroscience and The Center for Investigative Neuroscience: “AgeRelated Decline in Dopamine Transporters with [123I]ß-CIT SPECT.” Invited Speaker, Continuing Medical Education conference on “New Diagnostic & Management Strategies for Dementia” sponsored by Yale University School of Medicine Section of Geriatrics: “Developments in Pharmacologic Treatment of Cognitive Impairment and Dementia.” Invited Speaker, Alzheimer's Association, Southern Connecticut Chapter: “Memory and Aging.” Invited Speaker, Section of Neurobiology, Yale University School of Medicine, Woods Hole Retreat Symposium: “Neuroimaging Correlates of Apolipoprotein E-4 in Alzheimer's Disease” Woods Hole, MA. Invited Speaker, Alzheimer's Association, Southern Connecticut Chapter: “Pharmacologic Treatment of Alzheimer’s Disease.” Chester CT. Symposium Speaker and Chairman, American Association for Geriatric Psychiatry: “Neuroimaging Correlates of ApoE 4 in Alzheimer's Disease and Healthy Aging.” (educational symposium for annual meeting of AAGP) Invited Discussant, Luncheon Roundtable on “Neuroimaging.” (educational roundtable for annual meeting of AAGP) Invited Speaker, National Center of Excellence in Women’s Health at Yale and the Women’s Behavioral Health Division: “Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer’s Disease: A One-Year Randomized controlled Trial.” Invited Speaker, Preceptorship in Psychiatry, sponsored by Pfizer Inc: “Alzheimer’s Disease” at Yale University School of Medicine. Invited Speaker, Alzheimer’s Association (Connecticut) Education Conference: “Pharmacological Treatment of Alzheimer’s Disease: Present and Future.” Invited Speaker, Preceptorship in Psychiatry, sponsored by Pfizer Inc: “Alzheimer’s Disease” at Yale University School of Medicine. Invited Speaker, educational dinner on “Alzheimer’s Disease” sponsored by Novartis Pharmaceuticals. New Haven, CT. Invited Speaker, Symposium on “Cognition Enhancers, AntiAlzheimer and Neuroprotective Drugs” sponsored by the Institute for the Study of Aging and the Department of Pharmacology, Yale 6 C. H. van Dyck, M.D. 10/20/00 1/16/01 3/8/01 5/16/01 11/15/01 1/14/02 2/20/02 4/20/02 12/9/02 1/28/03 2/12/03 5/8/03 5/10/03 9/6/03 11/1/03 11/6/03 May 3, 2017 University School of Medicine: “Neuroimaging in Alzheimer’s Disease: Relevance for the Development of Therapeutic Agents.” Invited Speaker, Yale Psychiatric Alumni Association Meeting, featuring Contemporary Treatments in Geriatric Psychiatry: “Current and Future Pharmacologic Treatments for Alzheimer’s Disease.” Course Director and Speaker, Preceptorship in Alzheimer’s Disease, sponsored by Pfizer Inc. at Yale University School of Medicine. Course Director and Speaker, Preceptorship in Alzheimer’s Disease, sponsored by Pfizer Inc. at Yale University School of Medicine. Invited Speaker, Connecticut Geriatric Society, Stamford CT: “AgeRelated Memory Loss: Is It Ever Benign?” Invited Speaker, educational dinner on “Mild Cognitive Impairment” sponsored by Pfizer Pharmaceuticals. Westport, CT. Invited Speaker (Grand Rounds), Milford Hospital, Milford CT: “Early Diagnosis & Treatment for Alzheimer’s.” Invited Speaker (Grand Rounds), Masonic Home, Wallingford CT: “Mild Cognitive Impairment.” Invited Speaker, Neuroscience 2002 Symposium, “New Mechanisms: New Treatments” sponsored by Department of Psychiatry Yale University School of Medicine in Association with National Alliance for the Mentally Ill: “Alzheimer’s Disease: Pharmacotherapy and Brain Function.” Study Group Speaker, 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan PR: “Dopamine transporters in ADHD: Increased, decreased, or unchanged?” Invited Speaker (Grand Rounds), University of Connecticut, Farmington CT: “The Diagnosis and Treatment of Alzheimer’s Disease.” Invited Speaker (Medical Grand Rounds), Baystate Medical Center, Springfield MA: “Pharmacologic Treatment of Alzheimer’s Disease and Mild Cognitive Impairment.” Invited Speaker (Grand Rounds), Institute of Living, Hartford CT: “Pharmacologic Treatment of Alzheimer’s Disease and Mild Cognitive Impairment.” Invited Speaker, 6th International Conference AD/PD, Seville, Spain. “Memantine/Donepezil Dual Therapy is Superior to Placebo/Donepezil Therapy for Moderate to Severe Alzheimer’s Disease.” Invited Speaker, CME, Inc, Iselin NJ: “Alzheimer’s Disease: Diagnosis and Medication Mechanism of Actions to Maximize Patient Outcomes.” Invited Speaker, CME, Inc, Raleigh NC: “Alzheimer’s Disease: Diagnosis and Medication Mechanism of Actions to Maximize Patient Outcomes.” Invited Speaker, CME Symposium on “Emerging Management Strategies in Alzheimer’s Disease” sponsored by University of Minnesota, held in Boston, MA: “Maximizing Therapeutic Response: 7 C. H. van Dyck, M.D. 11/8/03 12/1/03-4/28/04 2/3/04 2/24/04 4/15/04 4/28/04 7/13/04 10/30/04 3/31/05 5/13/05 6/18/05 12/13/05 2/15/06 6/21/06 11/28/06 May 3, 2017 A Combination Approach to the Management of Alzheimer’s Disease.” Invited Speaker, CME, Inc, Newark NJ: “Alzheimer’s Disease: Diagnosis and Medication Mechanism of Actions to Maximize Patient Outcomes.” Faculty Speaker, "A Unique Advance in Alzheimer's Disease: The Namenda Teleconference Series," sponsored by Forest Laboratories. Invited Speaker, Adler Geriatric Assessment Center: “Memantine for Moderate to Severe Alzheimer’s Disease.” Invited Speaker, Symposium on “Assessing Current Practice In Alzheimer’s Disease” at AAGP annual meeting, Baltimore MD: “The ABCs of Alzheimer’s Disease Management: Understanding the Latest Advances in Pharmacologic and Nonpharmacologic Interventions for Alzheimer’s Disease.” Invited Speaker, educational dinner on “Alzheimer’s Disease” sponsored by Forest Pharmaceuticals. Ledyard, CT. Invited Speaker (Grand Rounds), Northampton VA Medical Center, Leeds MA: “Alzheimer's Disease Update: Current Status of Pathophysiology, Diagnosis, and Treatment.” Invited Speaker, Alzheimer’s Association Connecticut Chapter Future Forum, West Haven, CT. Invited Speaker, Massachusetts Psychiatric Society 2nd Annual Geriatric Psychiatry Conference: Controversies in Geriatric Psychiatry, Waltham MA: “Cholinesterase Inhibitors and Memantine: Just How Worthwhile are these Agents?” Invited Speaker, 2005 CT Alzheimer’s Association Educational Conference, Cromwell, CT: “Pharmacologic Treatments for Alzheimer's Disease: How Worthwhile are They?” Invited Speaker, Grand Rounds, Department of Psychiatry, Yale University School of Medicine: “Alzheimer’s Disease Update: The Treatment and The Story.” “How Worthwhile are Approved Treatments?” Invited Speaker, Categorical Seminar on “Dementia Imaging: Metabolism, Blood Flow, and Beyond,” Society of Nuclear Medicine Annual Meeting, Toronto, CA: “Clinical Features of Dementia: Evaluation, Disease Course, and Treatment.” Invited Speaker, Adler Geriatric Assessment Center, Yale-New Haven Hospital: “PET Imaging for the Clinical Evaluation of Dementia.” Invited Speaker (Grand Rounds), Institute of Living, Hartford CT: “Pharmacologic Treatments for Alzheimer’s Disease: How Worthwhile Are They?” Invited Speaker, Neurology/Neurosurgery Clinical Neuroscience Grand Rounds, Yale University School of Medicine: “The Apolipoprotein E4 Phenotype in Alzheimer's Disease.” Invited Speaker, Grand Rounds, Section of Geriatric Medicine, Yale University School of Medicine: “Present and Future Drug Therapy of Alzheimer’s Disease.” 8 C. H. van Dyck, M.D. 11/29/07 12/16/08 5/26/09 11/9/09 3/1/10 3/2/10 3/23/10 6/17/10 May 3, 2017 Invited Speaker, CT Alzheimer’s Association, Kensington, CT: Progress of Research and Treatment of Alzhemer’s Disease, “Is There Light at the End of the Tunnel?” Invited Speaker, Grand Rounds, Section of Geriatric Medicine, Yale University School of Medicine: “New and Emerging Treatments for Alzheimer’s Disease.” Invited Speaker, Grand Rounds, St. Vincent’s Medical Center, Bridgeport, CT: “Approved & Investigational Treatments for Alzheimer's Disease.” Invited Speaker, CT Alzheimer’s Association, Hamden, CT: “Overview of Alzheimer’s Disease & Other Forms of Dementia and Treatment/Research.” Invited Speaker, Yale Club of New York, New York, NY. Alzheimer’s Disease: The Science, The Story and Yale Reception and Presentation: “ß-Amyloid Imaging in Subjects at Risk for Alzheimer’s Disease.” Invited Speaker, Grand Rounds, Section of Geriatric Medicine, Yale University School of Medicine: “New and Emerging Treatments for Alzheimer’s Disease.” Invited Speaker, CT Alzheimer’s Association, Statewide Education Conference, Cromwell, CT: “Toward Primary Prevention Trials: AntiAmyloid Therapies and Amyloid Imaging in Individuals at Risk for Alzheimer’s Disease.” Invited Speaker, CT Alzheimer’s Association, New Canaan, CT: “New Medical Research for Individuals at Risk for Alzheimer’s Disease.” Other: 1993-Present 1993-Present 1994-Present 1994-Present 1997-2002 1997-2002 2000-2002 2001-Present 2002-Present 2004-Present Faculty, Program on Aging, Yale University School of Medicine Faculty, Claude D. Pepper Older Americans Independence Center, Yale University School of Medicine Adjunct Faculty, Fellowship in Geriatric Medicine and Clinical Epidemiology, Department of Medicine, Yale University School of Medicine Faculty, Fellowship in Geriatric Psychiatry, Department of Psychiatry, Yale University School of Medicine Board of Directors, Alzheimer's Association, Southern Connecticut Chapter Program Committee, Alzheimer's Association, Southern Connecticut Chapter Member of “Ask the Experts” panel (expert on Alzheimer’s disease) for HealthInfo web-based educational corporation. Steering Committee, Alzheimer’s Disease Cooperative Study (ADCS; NIH/NIA Consortium) Chairman, Medical Scientific Advisory Committee, Alzheimer's Association, Connecticut Chapter Steering Committee, Alzheimer’s Disease Neuroimaging Initiative (ADNI; NIH/NIA Consortium) 9 C. H. van Dyck, M.D. 2006-Present 2007-Present May 3, 2017 Genetics Working Group, Alzheimer’s Disease Neuroimaging Initiative (ADNI; NIH/NIA Consortium) Member, Interdepartmental Neuroscience Program (INP), Yale University 10 C. H. van Dyck, M.D. May 3, 2017 Grant and Contracts Received: Active Agency: NIH/NIA Grant Number: 1-R01-AG030457-01A1 Title of Grant: Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects Role on Project: Principal Investigator Total Costs / Total Direct Costs: $1,377,071 / $832,067 Dates of Project: 9-15-08 to 8-31-11; NCE to 8-31-12 Agency: NIH/NIA Grant Number: 1-R01-AG034953-01 (P.I. Doug Rothman) Title of Grant: 13C MRS Studies of Human Brain Mitochondrial Metabolism in Healthy Aging Subjects Role on Project: Co-Investigator Total Costs / Total Direct Costs: $2,052,625 / $1,240,257 Dates of Project: 7-1-10 to 6-30-14 Agency: NIH/NIA Grant Number: 2-U01AG024904-06 (P.I.: Michael W. Weiner) Title of Grant: Alzheimer's Disease Neuroimaging Initiative (ADNI) Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of California, San Diego Total Costs / Total Direct Costs: $400,000 / $320,000 (est.) Dates of Project: 9/30/2010 to 8/31/2015 Agency: NIH/NIA Grant Number: 5-U01-AG10483 (P.I. Paul Aisen) Title of Grant: Alzheimer’s Disease Cooperative Study (ADCS) Unit Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of California, San Diego Total Costs / Total Direct Costs: $500,000 / $400,000 (est.) Dates of Project: 7-1-06 to 6-30-12 Specific Projects thus far: 1) “Assessment Measures for Alzheimer’s Disease Primary Prevention Trials,” 2) “A Multicenter, Randomized, Double-Blind, PlaceboControlled Trial of Simvastatin to Slow the Progression of Alzheimer’s Disease,” 3) “Study of High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer’s Disease” (HIC #23455), 4) “A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer’s Disease” (HIC #0610001926), 5) “Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer Disease Prevention Research in People Over 75 Years Old” (HIC #0709003080), 6) “A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF-04494700 (TTP488) In Participants With Mild-To-Moderate Alzheimer’s Disease” (HIC 11 C. H. van Dyck, M.D. May 3, 2017 #801003458), 7) “A Randomized, Double-Blind, Placebo-Controlled, Two DoseArm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer’s Disease” (HIC#: 0811004451). Agency: NIH/NIA Grant Number: 1 RC2 AG036535 (P.I.: Michael W. Weiner) Title of Grant: Alzheimer's Disease Neuroimaging Initiative Grand Opportunity (ADNI-GO) Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of California, San Diego Total Costs / Total Direct Costs: $125,000 / $100,000 (est.) Dates of Project: 10/01/09 to 8/31/11 Agency: Genentech, Inc Title of Grant: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Disease (protocol number ABE4869g).” HIC #1103008271 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ Dates of Project: 11-15-11 to 7-1-15 Agency: Wyeth Research Title of Grant: “A Phase 2, Multicenter, 24-Month, Randomized, Third-Party Unblinded, Placebo-Controlled, Parallel-Group Amyloid Imaging Positron Emission Tomography (PET) and Safety Trial of ACC-001 and QS-21 Adjuvant in Subjects with Early Alzheimer’s Disease.” HIC #1101007937 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ Dates of Project: 6-13-11 to 7-1-14 Agency: Wyeth Research Title of Grant: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapinezumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Noncarriers (protocol number 3133K1-3000-US).” HIC: #1010007501 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 3-1-11 to 12-1-13 Agency: Wyeth Research Title of Grant: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapinezumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Carriers (protocol number 3133K1-3001-US).” HIC: #911005961 Role on Project: Principal Investigator 12 C. H. van Dyck, M.D. May 3, 2017 Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 5-1-10 to 5-1-13 Agency: Eli Lilly and Company Title of Grant: “Effect of LY2062430, an Anti-Amyloid Beta Monoclonal antibody, on the Progression of Alzheimer’s Disease as Compared to Placebo.” HIC #907005523 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 2-24-10 to 7-1-12 Agency: Bristol-Myers Squibb Company Title of Grant: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS708163 in the Treatment of Patients with Prodromal Alzheimer’s Disease.” HIC #907005506 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 11-4-09 to 12-31-12 Agency: Elan Pharmaceuticals Title of Grant: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients with Mild to Moderate Alzheimer’s Disease who are apolipoprotein E 4 Non-Carriers (AAB-301)” (includes open-label extension). HIC #801003387 and HIC #909005759 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $296,075 / $227,750 (est) Dates of Project: 3-12-08 to 7-1-11 Agency: Elan Pharmaceuticals Title of Grant: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients with Mild to Moderate Alzheimer’s Disease who are apolipoprotein E 4 Carriers (AAB-302)” (includes open-label extension). HIC #801003388 and HIC #909005759 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $296,075 / $227,750 (est) Dates of Project: 3-12-08 to 7-1-11 Agency: Wyeth Research Title of Grant: A phase IIa, multicenter, randomized, third-party unblinded, adjuvantcontrolled, multiple ascending dose, safety, tolerability and immunogenicity trial of ACC-001 with QS-21 adjuvant in subjects with mild to moderate Alzheimer’s disease” (includes open-label extension). HIC # 709003057 and HIC #1009007417 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $308,286 / $237,143 (est) Dates of Project: 12-12-07 to 7-1-11 13 C. H. van Dyck, M.D. May 3, 2017 Expired Agency: Alzheimer’s Association Grant Number: Investigator-Initiated Research Grant-07-60026 Title of Grant: Amyloid Binding In Subjects At Risk For Alzheimer’s Disease Role on Project: Principal Investigator Total Costs / Total Direct Costs: $239,965 / $218,151 Dates of Project: 7-1-07 to 6-30-10 Agency: American Health Assistance Foundation Grant Number: A2004-216 Title of Grant: Nicotinic Receptors in Subjects at Risk for Alzheimer’s Role on Project: Principal Investigator Total Costs / Total Direct Costs: $99,675 / $99,675 Dates of Project: 4-1-04 to 10-31-06 Agency: Alzheimer’s Association Grant Number: Investigator-Initiated Research Grant-01-2891 Title of Grant: Serotonergic Correlates of Psychosis in Alzheimer’s Disease Role on Project: Principal Investigator Total Costs / Total Direct Costs: $239,064 / $217,332 Dates of Project: 5-1-02 to 6-30-07 Agency: National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD) Grant Number: Independent Investigator Award Title of Grant: Serotonergic Correlates of Major Depression in Alzheimer’s Disease Role on Project: Principal Investigator Total Costs / Total Direct Costs: $99,126 / $91,784 Dates of Project: 7-1-01 to 3-15-07 Agency: NIH/NIMH Grant Number: 1 R01 MH58620-01A2 Title of Grant: Serotonin 5HT2A Receptors in Depression Role on Project: Principal Investigator Total Costs / Total Direct Costs: $824,761 / $568,635 Dates of Project: 3-20-00 to 2-28-06 Agency: Ethel F. Donaghue Women’s Health Investigator Program Grant Number: R05131 Title of Grant: Estrogen & 5-HT2A Receptors in Menopausal Women with Depression Role on Project: Principal Investigator Total Costs / Total Direct Costs: $49,971 / $49,971 Dates of Project: 7/1/04 to 6/30/06 14 C. H. van Dyck, M.D. May 3, 2017 Agency: NIH/NIA Grant Number: 1-UO1-AG024904 (P.I. Michael W. Weiner) Title of Grant: Alzheimer’s Disease Neuroimaging Initiative (ADNI) Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of California, San Diego Total Costs / Total Direct Costs: $329,075 / $263,260 (est.) Dates of Project: 9/30/04 to 8/31/10 (NCE) Agency: NIH/NIA Grant Number: 5-U01-AG10483 (P.I. Leon Thal) Title of Grant: Alzheimer’s Disease Cooperative Study (ADCS) Unit Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of California, San Diego Total Costs / Total Direct Costs: $500,000 / $400,000 (est.) Dates of Project: 7-1-01 – 6-30-06 Specific Projects: 1) “Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Vitamin E and Donepezil HCl (Aricept®) to Delay Clinical Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD),” 2) “A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer’s Disease,” 3) “Assessment Measures for Alzheimer’s Disease Primary Prevention Trials,” 4) “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer’s Disease,” 5) “Study of High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer’s Disease” HIC# 23455 Agency: NIH/NIA Grant Number: NIH/NIA: 5-U01-AG10483 (P.I. Leon Thal) Title of Grant: Alzheimer’s Disease Cooperative Study (ADCS) Unit Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of California, San Diego Total Costs / Total Direct Costs: $300,000 / $240,000 (est.) Dates of Project: 7-1-96 – 6-30-01 Specific Projects: 1) “A Multicenter, Double-Blind, Placebo-Controlled Study of Estrogen Replacement Therapy in Patients with Mild to Moderate Alzheimer's Disease: A Pilot Study of the Alzheimer's Disease Cooperative Study,” 2) “Multicenter, Placebo-Controlled Trial of Melatonin for Sleep Disturbance in Alzheimer’s Disease," 3) “Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Vitamin E and Donepezil HCl (Aricept®) to Delay Clinical Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD),” 4) “A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer’s Disease.” Agency: NIH/NIMH Grant Number: N01-MH90001 (P.I. Jeffrey Lieberman) Title of Grant: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE); Comparative Effectiveness of Antipsychotic Medications in Patients with Alzheimer’s Disease 15 C. H. van Dyck, M.D. May 3, 2017 Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of North Carolina Total Costs / Total Direct Costs: $150,000 / $120,000 (est.) Dates of Project: 10-1-99 to 9-30-04 Agency: Pfizer, Inc. Title of Grant: “A Phase 3, multi-center, randomized, double-blind, placebo-controlled 26-week trial to evaluate the efficacy and safety of Dimebon in patients with moderate to severe Alzheimer’s Disease.” HIC #909005682 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 2-3-10 to 7-1-12 Agency: Bristol-Myers Squibb Company Title of Grant: “A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS708163 in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease.” HIC#904004964 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 7-7-09 to 5-17-10 Agency: Medivation, Inc. Title of Grant: “CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil” (with open-label extension) HIC #0903004857 and HIC #1010007501 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 7-1-09 to 12-31-11 Agency: Bayer HealthCare Pharmaceuticals, Inc. Title of Grant: “An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BA 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with probable Alzheimer's disease compared to healthy volunteers.” Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 11-19-2008 to 8-20-09 Agency: Medivation, Inc. Title of Grant: Connection (DIM14): A Global Phase 3, Double-Blind, PlaceboControlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-ToModerate Alzheimer’s Disease” (with open-label extension) HIC #805003830 and HIC #901004625 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) 16 C. H. van Dyck, M.D. May 3, 2017 Dates of Project: 7-31-08 to 7-1-11 Agency: Abbott Laboratories Title of Grant: “A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors” HIC #711003285 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 7-29-08 to 5-26-09 Agency: Eli Lilly and Company Title of Grant: Effect of Gamma-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo (Protocol H6L-MC-LFAN)” (includes open-label extension. HIC #803003585 and HIC #1002006287 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $ / $ (est) Dates of Project: 6-1-08 to 7-1-11 Agency: Elan Pharmaceuticals Title of Grant: A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Safety, and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s disease” (includes open-label extension) HIC #712003331 and HIC #908005634 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $296,075 / $227,750 (est) Dates of Project: 3-5-08 to 3-17-10 Agency: GlaxoSmithKline Title of Grant: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE 4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-2) (includes openlabel extension phase). HIC #608001709, 711003271 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $300,000 / $230,769 (est) Dates of Project: 11-1-06 to 5-1-09 Agency: Myriad Pharmaceuticals, Inc. Title of Grant: Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type.” HIC # 608001710 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $156,000 / $120,000 (est) Dates of Project: 11-7-06 to 10-20-08 Agency: Myriad Pharmaceuticals, Inc. 17 C. H. van Dyck, M.D. May 3, 2017 Title of Grant: Phase 3 Multi-center, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type (includes open-label extension phase). HIC #0506000112, 608001770 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $500,000 / $384,615 (est) Dates of Project: 9-12-05 to 9-12-08 Agency: Elan Pharmaceuticals Title of Grant: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients with Mild to Moderate Alzheimer’s Disease (includes open-label extension phase). HIC #27280, 610001937 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $450,000 / $346,154 (est) Dates of Project: 4-1-05 to 9-30-08 Agency: Eli Lilly and Company Title of Grant: LY2062430: Multiple-Dose Safety in Subjects with Mild to Moderate Alzheimer’s Disease and Single-Dose Safety in Healthy Volunteers. HIC #0601001050 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $422,500 / $325,000 (est) Dates of Project: 9-1-06 to 9-1-08 Agency: Neurochem, Inc. Title of Grant: A Phase III Study of the Efficacy and Safety of Alzhemed™ in Patients with Mild to Moderate Alzheimer’s Disease. HIC #26729 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $675,000 / $519,230 (est) Dates of Project: 9-1-04 to 7-29-08 Agency: Sanofi-Synthelabo Research Title of Grant: A randomized, multi-center, double-blind, placebo-controlled, 18-month study of the efficacy of xaliproden in patients with mild-to-moderate dementia of the Alzheimer’s type. HIC #25926 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $304,519 / $234,245 Dates of Project: 4-22-04 to 12-31-07 Agency: Eisai Pharmaceuticals Title of Grant: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects With Mild Cognitive Impairment Sub Study: MRI Test Retest. E2020-A001412. HIC #25925 Role on Project: Principal Investigator 18 C. H. van Dyck, M.D. May 3, 2017 Total Costs / Total Direct Costs: $361,374 / $277,980 Dates of Project: 3-1-04 to 9-5-07 Agency: Merck Pharmaceuticals Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer’s Disease. HIC #25387 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $481,742 / $370,570 Dates of Project: 12-2-03 to 1-3-06 Agency: Forest Laboratories Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane in Patients with Moderate to Severe Dementia of the Alzheimer’s Type. (01-HIC #23637, 02-HIC #23654, open-label 03-HIC #25388) Role on Project: Principal Investigator Total Costs / Total Direct Costs: $547,250 / $420,961 Dates of Project: 3-26-03 to 10-13-05 Agency: Pfizer, Inc. Title of Grant: A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 weeks) after Single Dose and Steady State Therapy (2 weeks and 6 weeks) in Subjects with Mild Cognitive Impairment. HIC #25982 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $125,887 / $76,295 Dates of Project: 3-23-04 to 8-24-04 Agency: Mitsubishi Pharma Corporation Title of Grant: A Double-Blind, Placebo-Controlled Dose-Finding Study Evaluating the Safety and Efficacy of MKC-231, 80 mg b.i.d., and 20 mg and 80 mg q.d. in the Treatment of Mild to Moderate Alzheimer’s Disease. HIC #21975 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $39,566 / $30,435 Dates of Project: 10-17-03 to 10-19-04 Agency: Cortex Pharmaceuticals Title of Grant: Efficacy and Safety of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-Week Study. HIC #12757 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $128,700 / $99,000 Dates of Project: 4-17-02 to 7-22-03 Agency: Forest Laboratories 19 C. H. van Dyck, M.D. May 3, 2017 Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type (includes open-label extension phase). HIC #15034 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $477,760 / $367,507 Dates of Project: 6-6-02 to 10-22-04 Agency: Forest Laboratories Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer’s Type (includes open-label extension phase). HIC #12379,12380,12381 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $850,262 / $654,047 Dates of Project: 8-6-01 to 3-15-05 Agency: Janssen Pharmaceuticals Title of Grant: A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer’s disease (includes open-label extension phase). HIC #12222, 25095 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $329,140 / $253,185 Dates of Project: 6-27-01 to 4-7-04 Agency: Eisai Pharmaceuticals Title of Grant: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of The Safety and Efficacy of Donepezil Hydrochloride (E2020) In Patients With Severe Alzheimer’s Disease Followed by a 12 Week Open-Label Extension Period. HIC #12165 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $10,641 / $8,185 Dates of Project: 6-15-01 to 10-29-02 Agency: Neotherapeutics, Inc. Title of Grant: A Placebo-Controlled Dose-Titration Efficacy and Tolerability Study of Neotrofin in Patients with Probable Alzheimer’s Disease. HIC #12309 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $317,854 / $244,503 Dates of Project: 4-23-01 to 2-13-02 Agency: Janssen Pharmaceuticals Title of Grant: Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer’s disease: Safety and Efficacy of a Controlled Release Formulation (includes open-label extension phase). HIC #12090, 12632 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $178,590 / $137,377 20 C. H. van Dyck, M.D. May 3, 2017 Dates of Project: 3-12-01 to 7-7-03 Agency: Merck Pharmaceuticals Title of Grant: The Safety and Efficacy of MK-0966 25mg in Delaying the Progression of the Symptoms of Alzheimer's Disease in Patients with Probable AD (MK-126). HIC #11634 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $254,758 / $195,968 Dates of Project: 5-24-00 to 6-1-01 Agency: Cephalon, Inc. Title of Grant: A 6-Week, Double-Blind, Randomized, Placebo-Controlled, ParallelGroup Study to Evaluate the Safety and Efficacy of Provigil (Modafinil) Administered as Single Oral Doses of 100 mg/d and 400 mg/d (Phase A) and 200 mg/d (Phase B) in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD), followed by an 8-Week Open-Label Extension. HIC #11646 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $104,364 / $80,280 Dates of Project: 3-28-00 to 11-1-00 Agency: Eli Lilly and Company Title of Grant: Olanzapine Versus Risperidone or Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia. HIC #10610 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $187,731 / $144,409 Dates of Project: Dates of Award: 2-24-99 to 8-7-01 Agency: Merck Pharmaceuticals Title of Grant: The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer's Disease (MK-091). HIC #10668 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $471,666 / $362,820 Dates of Project: 2-22-99 to 11-15-00 Agency: Janssen Pharmaceuticals Title of Grant: Placebo controlled evaluation of galantamine in the treatment of Alzheimer’s Disease: Safety and efficacy under a slow-titration regimen (includes open-label extension phase). HIC #10535, 10964, 11589 Role on Project: Principal Investigator Total Costs / Total Direct Costs: $427,825 / $329,096 Dates of Project: 11-20-98 to 8-8-01 Agency: Takeda America Pharmaceuticals Title of Grant: A Randomized Double-Blind, Placebo Controlled, 12-Month Safety and Efficacy Trial of Idebenone (CV-2619) 360 mg tid in Patients with Probable Alzheimer's Disease. HIC #10097, 10098 Role on Project: Principal Investigator 21 C. H. van Dyck, M.D. May 3, 2017 Total Costs / Total Direct Costs: $578,626 / $445,097 Dates of Project: 4-13-98 to 3-25-99 Agency: Novartis Pharmaceuticals Corp. Title of Grant: An Open Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d. (12 mg/day) of Exelon™ in Patients with Mild to Severe Probable Alzheimer’s Disease in the Community Setting. HIC #9561 Role on Project: Principal Investigator Percent Effort: 5% Total Costs / Total Direct Costs: $365,061 / $280,816 Dates of Project: 7-15-97 to 6-2-00 Agency: Parke-Davis, Inc. Title of Grant: A 52 Week, Randomized, Double-Blind, Placebo-Controlled, ParallelGroup, Multicenter Study of Milameline (CI-979/RU 35926) in Patients with Probable Alzheimer’s Disease with Long-Term Open-Label Extension Role on Project: Principal Investigator Total Costs / Total Direct Costs: $92,956 / $71,505 Dates of Project: 9-1-96 to 10-1-97 Agency: Eisai America, Inc. Title of Grant: A 54 Week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer’s Disease with a Staged Crossover to Open-Label Donepezil Hydrochloride (E2020) Treatment Role on Project: Principal Investigator Total Costs / Total Direct Costs: $10,000 / $7,692 Dates of Project: 7-1-96 to 7-1-97 Agency: Mediolanum Pharmaceuticals Title of Grant: A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of Eptastigmine Following Four-Week, Step-Wise Dose Escalations in Patients with Probable Alzheimer’s Disease Role on Project: Principal Investigator (Also Principal Investigator of multicenter SPECT trial examining the effects of Eptastigmine on regional cerebral blood flow in 72 Alzheimer's disease patients) Total Costs / Total Direct Costs: $522,164 / $401,665 Dates of Project: 7-1-96 to 1-1-98 Agency: American Federation for Aging Research (AFAR) Title of Grant: Motor Correlates of Striatal Dopamine Transporter Binding with [123I]ßCIT SPECT in Older Adults Role on Project: Principal Investigator Total Costs / Total Direct Costs: $40,000 / $40,000 Dates of Project: 7-1-95 to 12-31-96 Agency: Forest Laboratories 22 C. H. van Dyck, M.D. May 3, 2017 Title of Grant: Clinical Evaluation of the Safety and Efficacy of AF102B vs. Placebo in the Treatment of Patients with Dementia of the Alzheimer's Type Role on Project: Principal Investigator Total Costs / Total Direct Costs: $332,371 / $255,670 Dates of Project: 1-1-95 to 10-1-97 Agency: Glaxo, Inc. Title of Grant: A Controlled Study of Ondansetron in the Treatment of Primary Degenerative Dementia of the Alzheimer's Type Role on Project: Principal Investigator Total Costs / Total Direct Costs: $110,000 / $84,615 Dates of Project: 12-1-93 to 4-1-95 Agency: Forest Laboratories Title of Grant: Efficacy of Extended-Release Oral Physostigmine in Alzheimer's Disease and Senile Dementia of the Alzheimer Type Role on Project: Principal Investigator Total Costs / Total Direct Costs: $504,500 / $388,077 Dates of Project: 6-1-93 to 7-1-97 Agency: DuPont Merck Pharmaceuticals, Inc. Title of Grant: Evaluation of Tc-99m Bicisate in Healthy Elderly Volunteers and Patients with Mild to Moderate Dementia of the Alzheimer's Type Role on Project: Principal Investigator (also Principal Investigator of multicenter SPECT trial examining the effects of Linopirdine on regional cerebral blood flow in 80 Alzheimer's disease patients) Total Costs / Total Direct Costs: $280,000 / $215,385 Dates of Project: 7-1-92 to 7-31-94 Agency: NIMH Grant Number: 1 R03 MH47459-01A1 Title of Grant: Comparison of IMP & HMPAO Cerebral SPECT Images in Alzheimer's Disease Role on Project: Principal Investigator Total Costs / Total Direct Costs: $84,000 / $50,000 Dates of Project: 9-15-91 to 8-31-93 23 C. H. van Dyck, M.D. May 3, 2017 Bibliography: Original Articles 1. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI: Clarifying confusion: The Confusion Assessment Method (CAM). A new method for detection of delirium. Ann Intern Med 1991; 113(12):941-948. 2. Rosen MI, Bridge TP, O'Malley SS, Pearsall HR, Martini BL, O'Connor PG, BrettSmith H, Thomas HM, van Dyck CH, Woods SW, Kosten TR: Peptide T treatment of cognitive impairment in HIV+ intravenous drug users. Am J Addictions 1992;1(3):1-7. 3. Laruelle M, van Dyck CH, Abi-Dargham A, Zea-Ponce Y, Zoghbi SS, Charney DS, Baldwin RM, Hoffer PB, Kung HF, Innis RB: Compartmental modeling of [123I]IBF binding to dopamine D2 receptors in healthy subjects. J Nucl Med 1994;35:743-754. 4. van Dyck CH, Rosen MI, Thomas HM, McMahon TJ, Wallace EA, O'Connor PG, Sullivan M, Krystal JH, Hoffer PB, Woods SW, Kosten TR: SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Res Neuroimaging 1994;55:181-191. 5. Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CH, Price LH, Zubal G, Hoffer PB, Charney DS: Opiate dependence and withdrawal: Preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse 1995;21:47-63. 6. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Age-related decline in striatal dopamine transporter binding with Iodine-123-ß-CIT SPECT. J Nucl Med 1995;36:11751181. 7. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB: SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182-1190. 8. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Price LH, Leckman JF, Innis RB: [123I]ß-CIT SPECT imaging demonstrates increased striatal dopamine transporter binding in Tourette's syndrome. Am J Psychiatry 1995;152:1359-1361. 9. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck CH, Hoffer PB, Innis RB: Decreased singlephoton emission computed tomographic [123I]ß-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598. (Correction of authorship list. Ann Neurol 1996;39:417.) 24 C. H. van Dyck, M.D. May 3, 2017 10. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck CH, Hoffer PB, Innis RB: [123I]ß-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237. 11. van Dyck CH, Seibyl JP, Stubbs JB, Zoghbi SS, Baldwin RM, Zea-Ponce Y, Charney DS, Hoffer PB, Innis RB: Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF. Nucl Med Biol 1996;23:9-15. 12. Wallace EA, Wisniewski G, Zubal G, van Dyck CH, Pfau SE, Smith EO, Rosen MI, Sullivan MC, Woods SW, Kosten TR: Acute cocaine effects on absolute cerebral blood flow. Psychopharmacology 1996;128:17-20. 13. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Neumeyer J, Charney DS, Hoffer PB, Innis RB: Reproducibility of iodine-123-ß-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222-228. 14. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza C, Erdos J, McCanceKatz E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal J, Charney DS, Innis RB: SPECT imaging of amphetamine-induced dopamine activity in drug free schizophrenic subjects. Proc Natl Acad Sci 1996;93:9235-9240. PMCID: PMC38625. 15. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Wisniewski G, Narayan M, Bennett A, Delaney R, Bronen R, Hoffer PB: Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease. J Nucl Med 1996;37(11):1749-1755. 16. Arnsten AFT, Lin CH, van Dyck CH, Stanhope KJ: The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging 1997;18:21-28. 17. van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Lin CH, Pearsall HR, Woods SW, Kosten TR: Sustained-release methylphenidate for cognitive impairment in HIV-1–infected drug abusers: A pilot study. J Neuropsychiatry Clin Neurosci 1997;9:29-36. 18. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Nelson JC, Arnsten AFT, Hoffer PB: The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 1997;132(3):217-226. 19. Seibyl JP, Marek KL, Sheff K, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Charney DS, Henry, E, van Dyck CH, Hoffer PB, Innis RB: Test/retest reproducibility of [123I]ß-CIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997;38:1453-1459. 20. Gelernter J, van Dyck CH, van Kammen DP, Malison R, Price LH, Cubells JF, Berman R, Charney DS, and Heninger G: Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 1997;74:497-500. 25 C. H. van Dyck, M.D. May 3, 2017 21. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M: Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-767. 22. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB: Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]ßCIT SPECT. Am J Psychiatry 1998;155:832-834. 23. Seibyl JP, Marek KL, Sheff K, Zoghbi SS, Baldwin RM, Charney DS, van Dyck CH, Innis RB: Iodine-123-ß-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-1508. 24. van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden M, Okereke O, Varma P, Seibyl JP, Hoffer PB: The absence of an apolipoprotein E 4 allele is associated with increased parietal rCBF asymmetry in Alzheimer's disease. Arch Neurol 1998;55:14601466. 25. Malison RT, Price LH, Berman RM, van Dyck CH, Pelton GH, Carpenter LL, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS: Reduced brain serotonin transporter availability in major depression as measured by [123I]-2ß-carbomethoxy-3ß–(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090-1098. 26. Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ, and The Eptastigmine Study Group (includes van Dyck CH): Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease. Neurology 1999;52:700-708. 27. Tan P-Z, Baldwin RM, van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB: Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol 1999;26:601-608. 28. Verhoeff NPLG, Soares JC, D’Souza CD, Gil R, Degen K, Abi-Dargham A, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB: [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res Neuroimaging 1999;91:163-173. 29. van Dyck CH, Newhouse P, Falk WE, Mattes JA: Extended-release physostigmine in Alzheimer's disease: a multicenter, double-blind, 12-week study with dose-enrichment. Arch Gen Psychiatry 2000;57:157-164. 30. van Dyck CH, Tan P-Z, Baldwin RM, Amici LA, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB: PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. J Nucl Med 2000;41:234-241. 26 C. H. van Dyck, M.D. May 3, 2017 31. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA 2000;283:1007-1015. 32. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza C, Krystal JH, Seibyl JP, Baldwin RM, Innis RB: Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]ß-CIT SPECT. Biol Psychiatry 2000;47:371379. 33. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, Baldwin RM, Innis RB: Age-related decline in central serotonin transporter availability with [123I]ß-CIT SPECT. Neurobiol Aging 2000;21:497-501. 34. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and the Galantamine USA-10 Study Group (includes van Dyck CH): A-5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276. 35. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AFT: The alpha-2Aadrenoceptor agonist, guanfacine increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 2000;23:240-249. 36. van Dyck CH, Soares J, Tan P-Z, Staley JK, Baldwin RM, Amici LA, Fu X, Garg PK, Seibyl JP, Charney DS, Innis RB: Equilibrium modeling of 5-HT2A receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol 2000;27:715-722. 37. van Dyck CH: Neuroimaging in Alzheimer’s disease: Relevance for treatment. Current Psychiatry Reports 2001;3:13-19. 38. Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB, and Laruelle M: The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant chance in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001;24:553-560. 39. Soares JC, van Dyck CH, Tan P-Z, Zoghbi SS, Garg P, Soufer R, Baldwin RM, Fujita M, Staley JK, Fu X, Amici LA, Seibyl J, Innis RB: Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Res Neuroimaging 2001;106:81-93. 40. Staley JK, van Dyck CH, Tan P, Al-Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin R, Innis RB: Comparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies. Nucl Med Biol 2001;28: 271-279. 27 C. H. van Dyck, M.D. May 3, 2017 41. Marek KL, Innis RB, van Dyck CH, Fussell B, Early M, Eberly S, Oakes D, Seibyl JP: [123I]ß-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001;57:2089-2094. 42. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB: Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43. 43. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 2002;159(2):309-312. 44. Grundman M, Sencakova D, Jack CR Jr, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study: Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002;19:23-27. 45. Lappalainen J, Kranzler HR, Malison R, Price LH, van Dyck CH, Rosenheck RA, Cramer J, Southwick S, Charney DS, Krystal JK, Gelernter J: A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch Gen Psychiatry 2002;59:825-831. 46. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, Staley JK, Garg PK, Seibyl JP, Innis RB. Increase in prefrontal cortex serotonin2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160(8):1522-1524. 47. Grundman M, Jack CR, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas RG, Thal LJ. Hippocampal volume is associated with memory but not nonmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci 2003;20(3):241-248. 48. Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A, Seneca N, Tipre D, DeNucci CC, Iida H, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP, Baldwin RM, Innis RB. Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003;30:1620-1629. 49. van Dyck, CH. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. CNS Spectr 2004;9(7 Suppl 5):24-28. 50. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, CahnWeiner D, Thal LJ, and the Alzheimer’s Disease Cooperative Study. Mild Cognitive Impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61(1):59-66. 28 C. H. van Dyck, M.D. May 3, 2017 51. van Dyck, CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, Baldwin RM, Innis RB, Gelernter J. Central serotonin transporter availability measured with [123I]ß-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004;161(3):525-531. 52. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, van Dyck CH, Baldwin RM, Seibyl JP, Charney DS, Innis RB. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 2004;56(7):497-502. 53. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal, LJ. Vitamin E and donepezil for the treatment of Mild Cognitive Impairment. N Engl J Med 2005;352(23):2379-2388. 54. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J. Increased dopamine transporter availability associated with the 9-repeat allele of SLC6A3 gene. J Nucl Med 2005;46 745-751. 55. Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study. Sex, apolipoprotein E epsilon4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005, 62(6):953-7. 56. Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O’Malley S, Baldwin R, Jatlow P, Verhoeff NPLG, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical -aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. Arch Gen Psychiatry 2005, 62;877-888. 57. Staley JK, van Dyck CH, Weinzimmer D, Brenner E, Baldwin RM, Tamagnan GD, Riccardi P, Mitsis E, Seibyl JP. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: Feasibility and reproducibility. J Nucl Med 2005;46:1466-1472. 58. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB, van Dyck CH. Striatal dopamine transporter availability with [123I]ß-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology 2005;183(2):181189. 59. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005;11(4):353-368. 29 C. H. van Dyck, M.D. May 3, 2017 60. van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in Alzheimer's disease patients maintained on donepezil. Am J Geriatr Psychiatry 2006; 14(5):428-437. 61. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, MacAvoy M, Gelernter J, van Dyck CH. Apolipoprotein E 4 allele is unrelated to cognitive or functional decline in Alzheimer’s disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006;22(1):73-82. 62. Basso M, Yang J, Warren L, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Volumetry of amygdala and hippocampus and memory performance in Alzheimer’s disease. Psychiatry Res Neuroimaging 2006;146(3):251-261. 63. Zuo L, van Dyck CH, Luo X, Kranzler HR, Yang BZ, Gelernter J. Variation at APOE and STH loci and Alzheimer's disease. Behav Brain Funct 2006;2:13. PMCID: PMC1526745. 64. Zhang H, Ozbay F, Lappalainen J, Kranzler HR, van Dyck CH, Charney DS, Price LH, Southwick S, Yang BZ, Rasmussen A, Gelernter J. Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet 2006;141(4):387-393. PMCID: PMC2567822. 65. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O’Malley S, van Dyck CH. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 2006;26(34):8707-8714. 66. Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E 4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol Aging 2006;27(10):1416-1424. 67. Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. 2A-Adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem 2006;13(6):770-776. PMCID: PMC1783631. 68. Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis. Alzheimer Dis Assoc Disord 2006;20(4):255-262. 69. Zdanys KF , Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E 4 allele increases risk for psychotic symptoms in Alzheimer’s disease. Neuropsychopharmacology 2007;32(1):171179. 30 C. H. van Dyck, M.D. May 3, 2017 70. Mitsis EM, Cosgrove KP, Staley JK, Frohlich EB, Bois F, Tamagnan GD, Estok KM, Seibyl JP, van Dyck CH. [123I]5-IA-85380 SPECT imaging of ß2-nicotinic acetylcholine receptor availability in the aging human brain. Ann NY Acad Sci 2007;1097:168-170. 71. Tampi RR, van Dyck CH. Memantine: Efficacy and safety in mild-to-severe Alzheimer's disease. Neuropsychiatric Disease and Treatment 2007;3(2):245-258. 72. van Dyck CH, Tariot PN, Meyers B, Resnick EM; for the Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21(2):136-143. 73. Cosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, Perry E, Maciejewski PK, Epperson CN, Allen S, O’Malley S, Mazure CM, Seibyl JP, van Dyck CH, Staley JK. [123I]5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: Effects of sex and menstrual cycle phase. J Nucl Med 2007;48:1633-1640. 74. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group (includes van Dyck CH). Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebo-controlled trial. Curr Alzheimer Res 2008;5(1):83-89. 75. Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. The views of AD patients and their study partners on proxy consent for clinical trial enrollment. Am J Geriatr Psychiatry 2008;16(3):240-247. 76. van Dyck CH, Avery RA, MacAvoy MG, Marek KL, Quinlan DM, Baldwin RM, Seibyl JP, Innis RB, Arnsten AFT. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiol Aging 2008;29(8):1237-1246. Epub 2007 Mar 23. 77. Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials. Am J Geriatr Psychiatry 2008;16(7):568-574. Epub 2008 Jun 12. 78. Jack CR Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ; Members of the Alzheimer's Disease Cooperative Study (ADCS) (includes van Dyck CH). Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 2008;29(9):1285-1295. PMCID: PMC2768818. 79. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008;300(15):1774-1783. PMCID: PMC2684821. 31 C. H. van Dyck, M.D. May 3, 2017 80. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; On behalf of the MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial. Neurology 2008;71(21):1702-1708. 81. van Dyck CH. Imaging microglial activation in Alzheimer's disease: What does it mean? Biol Psychiatry 2008;64(10):833-834. 82. van Dyck CH, Lyness JM, Rohrbaugh RM, Siegal AP. Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home study. Int Psychogeriatr 2009;21(1):138-147. 83. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Episodic memory loss is related to hippocampal-mediated betaamyloid deposition in elderly subjects. Brain 2009;132(Pt 5):1310-1323. PMCID: PMC2677792. 84. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009 May;132(Pt 5):1355-65. PMCID: PMC2677798. 85. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group (includes van Dyck CH). Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009;72(24):2115-2121. 86. Mitsis EM, Cosgrove KP, Staley JK, Bois F, Frohlich EB, Tamagnan GD, Estok KM, Seibyl JP, van Dyck CH. Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT. Neurobiol Aging 2009 Sep;30(9):1490-1497. Epub 2008 Feb 1. 87. Mitsis EM, Reech KM, Bois F, Tamagnan GD, MacAvoy MG, Seibyl JP, Staley JK, van Dyck CH. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med 2009;50:1455-1463. 88. Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM, MacAvoy MG, Staley JK, van Dyck CH. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer’s disease with [18F]deuteroaltanserin and PET. Psychiatry Res Neuroimaging 2009;173(3):212-217. 89. Zdanys KF, Kleiman TG, Zhang H, Ozbay F, MacAvoy MG, Gelernter J, van Dyck CH. BDNF variants, premorbid educational attainment, and disease characteristics in Alzheimer’s disease: An exploratory study. J Alzheimers Dis 2009;17(4):887-98. 32 C. H. van Dyck, M.D. May 3, 2017 90. Hains AB, Vu MAT, Maciejewski PK, van Dyck CH, Gottron M, Arnsten AFT. Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Proc Natl Acad Sci 2009;106(42):17957-62. 91. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24):2061-70. 92. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM; the Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci 2009;106(49):2095420959. 93. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group (includes van Dyck CH). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302(23):2557-64. 94. Rimol LM, Agartz I, Djurovic S, Brown AA, Roddey JC, Kähler AK, Mattingsdal M, Athanasiu L, Joyner AH, Schork NJ, Halgren E, Sundet K, Melle I, Dale AM, Andreassen OA; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Sex-dependent association of common variants of microcephaly genes with brain structure. Proc Natl Acad Sci 2010 Jan 5;107(1):384-8. 95. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage. 2010 Nov 15;53(3):1051-63. 96. Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50(4):1427-37. 97. Stein JL, Hua X, Lee S, Ho AJ, Leow AD, Toga AW, Saykin AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Dechairo BM, Potkin SG, Weiner MW, Thompson P; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Voxelwise genome-wide association study (vGWAS). Neuroimage. 2010 Nov 15;53(3):1160-74. 98. Ho AJ, Stein JL, Hua X, Lee S, Hibar DP, Leow AD, Dinov ID, Toga AW, Saykin AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Stephan DA, DeCarli CS, DeChairo BM, Potkin SG, Jack CR Jr, Weiner MW, Raji CA, Lopez OL, Becker JT, Carmichael OT, Thompson PM; Alzheimer's 33 C. H. van Dyck, M.D. May 3, 2017 Disease Neuroimaging Initiative (includes van Dyck CH). A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci 2010 May 4;107(18):8404-9. 99. Wolk DA, Dickerson BC; the Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci 2010 Jun 1;107(22):10256-61. 100. Xu C, Wang Z, Fan M, Liu B, Song M, Zhen X, Jiang T; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. Neuroreport 2010 Aug 23;21(12):802-7. 101. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative investigators (includes van Dyck CH). Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging 2010 Aug;31(8):1452-62. 102. Vounou M, Nichols TE, Montana G; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage. 2010 Nov 15;53(3):1147-59. 103. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010 Nov 1;68(9):854-60. 104. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, van Dyck CH, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS. Docosahexaenoic Acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010 Nov 3;304(17):1903-11. 105. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011 Jan 4;76(1):69-79. 106. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology. 2011 Jun;259(3):844-51. Epub 2011 Apr 5. 34 C. H. van Dyck, M.D. May 3, 2017 107. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group (includes van Dyck CH). Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424-35. Epub 2011 Apr 8. 108. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mildto-moderate Alzheimer's disease: Two Phase 3 studies. Curr Alzheimer Res. 2011 Aug 1;8(5):592-606. 109. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct;68(10):1257-66. Epub 2011 Jun 13. 110. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011 Aug 9;77(6):556-63. Epub 2011 Jul 27. 111. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M. Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011 Sep 27;77(13):1253-1262. 112. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011 Oct 25;77(17):1619-28. Epub 2011 Oct 12. 113. Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, Soininen H, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One. 2011;6(10):e25446. Epub 2011 Oct 13. 114. Mattila J, Koikkalainen J, Virkki A, van Gils M, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng 2012 Jan;59(1):234-40. Epub 2011 Oct 10. 115. Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Alzheimer disease biomarkers are associated with body mass index. Neurology. 2011 Nov 22;77(21):1913-20. 35 C. H. van Dyck, M.D. May 3, 2017 116. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012 Jan 10;78(2):84-90. Epub 2011 Dec 21. 117. Chu C, Hsu AL, Chou KH, Bandettini P, Lin C; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images. Neuroimage. 2012 Mar;60(1):59-70. Epub 2011 Dec 1. 118. Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT, Macciardi F, Potkin SG; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸ fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. Biochim Biophys Acta. 2012 Mar;1822(3):457-66. Epub 2011 Sep 19. 119. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, MartinCook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, 36 C. H. van Dyck, M.D. May 3, 2017 Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3985-90. Epub 2012 Feb 16. 120. Koikkalainen J, Pölönen H, Mattila J, van Gils M, Soininen H, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Improved classification of Alzheimer's disease data via removal of nuisance variability. PLoS One. 2012;7(2):e31112. Epub 2012 Feb 13. 121. Johnstone D, Milward EA, Berretta R, Moscato P; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Multivariate protein signatures of preclinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One. 2012;7(4):e34341. Epub 2012 Apr 2. 122. Lo RY, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Predicting missing biomarker data in a longitudinal study of Alzheimer disease. Neurology. 2012 May 1;78(18):1376-82. Epub 2012 Apr 4. 123. Yuan L, Wang Y, Thompson PM, Narayan VA, Ye J; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage. 2012 Jul 2;61(3):622-32. Epub 2012 Mar 29. 124. Silver M, Montana G; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Fast identification of biological pathways associated with a quantitative trait using group lasso with overlaps. Stat Appl Genet Mol Biol. 2012 Jan 6;11(1):Article 7. doi: 10.2202/1544-6115.1755. 125. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, Toro R, Appel K, Bartecek R, Bergmann Ø, Bernard M, Brown AA, Cannon DM, Chakravarty MM, Christoforou A, Domin M, Grimm O, Hollinshead M, Holmes AJ, Homuth G, Hottenga JJ, Langan C, Lopez LM, Hansell NK, Hwang KS, Kim S, Laje G, Lee PH, Liu X, Loth E, Lourdusamy A, Mattingsdal M, Mohnke S, Maniega SM, Nho K, Nugent AC, O'Brien C, Papmeyer M, Pütz B, Ramasamy A, Rasmussen J, Rijpkema M, Risacher SL, Roddey JC, Rose EJ, Ryten M, Shen L, Sprooten E, Strengman E, Teumer A, Trabzuni D, Turner J, van Eijk K, van Erp TG, van Tol MJ, Wittfeld K, Wolf C, Woudstra S, 37 C. H. van Dyck, M.D. May 3, 2017 Aleman A, Alhusaini S, Almasy L, Binder EB, Brohawn DG, Cantor RM, Carless MA, Corvin A, Czisch M, Curran JE, Davies G, de Almeida MA, Delanty N, Depondt C, Duggirala R, Dyer TD, Erk S, Fagerness J, Fox PT, Freimer NB, Gill M, Göring HH, Hagler DJ, Hoehn D, Holsboer F, Hoogman M, Hosten N, Jahanshad N, Johnson MP, Kasperaviciute D, Kent JW Jr, Kochunov P, Lancaster JL, Lawrie SM, Liewald DC, Mandl R, Matarin M, Mattheisen M, Meisenzahl E, Melle I, Moses EK, Mühleisen TW, Nauck M, Nöthen MM, Olvera RL, Pandolfo M, Pike GB, Puls R, Reinvang I, Rentería ME, Rietschel M, Roffman JL, Royle NA, Rujescu D, Savitz J, Schnack HG, Schnell K, Seiferth N, Smith C, Steen VM, Valdés Hernández MC, Van den Heuvel M, van der Wee NJ, Van Haren NE, Veltman JA, Völzke H, Walker R, Westlye LT, Whelan CD, Agartz I, Boomsma DI, Cavalleri GL, Dale AM, Djurovic S, Drevets WC, Hagoort P, Hall J, Heinz A, Jack CR Jr, Foroud TM, Le Hellard S, Macciardi F, Montgomery GW, Poline JB, Porteous DJ, Sisodiya SM, Starr JM, Sussmann J, Toga AW, Veltman DJ, Walter H, Weiner MW; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH); EPIGEN Consortium; IMAGEN Consortium; Saguenay Youth Study Group, Bis JC, Ikram MA, Smith AV, Gudnason V, Tzourio C, Vernooij MW, Launer LJ, DeCarli C, Seshadri S; Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium, Andreassen OA, Apostolova LG, Bastin ME, Blangero J, Brunner HG, Buckner RL, Cichon S, Coppola G, de Zubicaray GI, Deary IJ, Donohoe G, de Geus EJ, Espeseth T, Fernández G, Glahn DC, Grabe HJ, Hardy J, Hulshoff Pol HE, Jenkinson M, Kahn RS, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meyer-Lindenberg A, Morris DW, Müller-Myhsok B, Nichols TE, Ophoff RA, Paus T, Pausova Z, Penninx BW, Potkin SG, Sämann PG, Saykin AJ, Schumann G, Smoller JW, Wardlaw JM, Weale ME, Martin NG, Franke B, Wright MJ, Thompson PM; Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012 Apr 15;44(5):552-61. doi: 10.1038/ng.2250. 126. Chapman SB, Cotman CW, Fillit HM, Gallagher M, van Dyck CH. Clinical trials: new opportunities. J Gerontol A Biol Sci Med Sci. 2012 Jun;67(7):773-80. Epub 2012 May 8. 127. Farlow M, Arnold SE, van Dyck CH, Aisen PS, MD, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012 Jul;8(4):261-71. Epub 2012 Jun 5. 128. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HF, Berman RM. Safety and tolerability of the gamma secretase inhibitor avagacestat in a Phase 2 study in mild-tomoderate Alzheimer’s disease. Arch Neurol, in press. Papers Submitted 129. Galasko D, Bell J, Kupiec J, Sabbagh M, van Dyck CH, Thomas RG, Aisen PS. 38 C. H. van Dyck, M.D. May 3, 2017 A randomized clinical trial of an inhibitor of RAGE-Aβ interactions in mild to moderate AD, in preparation. Chapters, Books, Letters 1. van Dyck CH, Seibyl JP, Zubal IG, Innis RB: Quantitation of neuroreceptors: a need to increase imaging resolution? (Letter to the Editor) J Nucl Med 1996;37(11):1911-1912. 2. Arnsten AFT, van Dyck CH: Monoamine and acetylcholine influences on higher cognitive functions in nonhuman primates: relevance to the treatment of Alzheimer's disease, in Brioni JD, Decker MW (eds): Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. Wiley-Liss, Inc., New York, 1997, pp. 63-86. 3. Naftolin FN, van Dyck CH. Commentary on: Shumaker SA, Legault C, Rapp SR, et al for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Womens Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662. Published in: First to Know (serial online http://www.menopause.org/news.html#june1); June 2003. Cleveland, OH: The North American Menopause Society. 4. Kugaya A, Epperson CN, van Dyck, CH, Fujita M, Innis RB. Estradiol effects on the postmenopausal brain (Letter to the Editor). Am J Psychiatry 2004;161(11):2136. 5. Mitsis EM, van Dyck CH. Neuroimaging in Alzheimer’s disease and Mild Cognitive Impairment, in Sun M-K (ed): Research Progress in Alzheimer’s Disease and Dementia (vol. 1). Nova Science, New York, 2006, pp. 1-24. 6. Tampi RR, van Dyck CH. Behavioral and Psychological Symptoms of Alzheimer’s Disease, in Sun M-K (ed): Research Progress in Alzheimer’s Disease and Dementia (vol. 2). Nova Science, New York, 2007, pp. 251-272. Published Abstracts 1. Inouye SK, van Dyck CH, Siegal AP, Horwitz RI: Clarifying confusion: A new screening method for identifying acute confusional state. Clinical Research 1989;37(2):314A. 2. Alessi C, Balkin S, Pompei P, Inouye S, van Dyck C: Validity of the Confusion Assessment Method: A new screening test for delirium in older patients. J Am Geriatr Soc 1990;38(8):A42. 3. van Dyck CH, Woods SW, O'Malley SS, Price LH, McDougle CJ, Kosten TR: SPECT regional cerebral blood flow in HIV disease. American Psychiatric Association 144th Annual Meeting, New Research Program and Abstracts 1991, p.79. 39 C. H. van Dyck, M.D. May 3, 2017 4. Thomas HM, van Dyck CH, Rosen MI, Waugh ME, Pearsall HR, Woods SW, Kosten TR: Characterization of buprenorphine withdrawal. American Psychiatric Association 144th Annual Meeting, New Research Program and Abstracts 1991, p.84. 5. Rosen MI, Thomas HM, Pearsall HR, van Dyck CH, Woods SW, Kosten TR: Peptide T for cognitively impaired HIV positive patients. American Psychiatric Association 144th Annual Meeting, New Research Program and Abstracts 1991, p.173. 6. van Dyck CH, Woods SW, O'Malley SS, Martini BL, McDougle CJ, Price LH, Krystal JH, Hoffer PB, Kosten TR: SPECT regional cerebral blood flow in HIV infected drug abusers. Problems of Drug Dependence 1991, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. 7. Rosen MI, Bridge TP, O'Malley SS, Martini BL, O'Connor PG, Brett-Smith H, Thomas HM, Pearsall HR, van Dyck CH, Woods SW, Kosten TR: Peptide T treatment of cognitive impairment in HIV+ intravenous drug users. Problems of Drug Dependence 1991, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. 8. Thomas HM, van Dyck CH, Rosen MI, Waugh ME, O'Connor PG, Pearsall HR, Hoffer PB, Woods SW, Kosten TR: Regional cerebral blood flow changes in naltrexone precipitated withdrawal from buprenorphine. Problems of Drug Dependence 1991, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. 9. Wallace EA, van Dyck CH, Zubal G, Pfau SE, Wisniewski G, Rosen MI, Pearsall HR, Hoffer PB, Kosten TR, Woods SW: Regional cerebral blood flow effects of acute cocaine infusion. Problems of Drug Dependence 1993, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. 10. van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Pearsall HR, Woods SW, Kosten TR: Methylphenidate for cognitive impairment in HIV-infected drug abusers: A pilot study. Problems of Drug Dependence 1993, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. 11. Laruelle M, van Dyck CH, Bradberry CW, Malison R, Al-Tikriti M, Zoghbi SS, ZeaPonce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Displacement of [123I]IBF equilibrium binding by d-amphetamine to measure in vivo dopamine release. J Nucl Med 1993;34(5):48P. 12. Laruelle M, Al-Tikriti M, van Dyck CH, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine displacement of [123I]IBF equilibrium binding in primates: A new paradigm to investigate d-amphetamine induced dopamine release. International Meeting of Schizophrenia Research 1993. 40 C. H. van Dyck, M.D. May 3, 2017 13. van Dyck CH, Laruelle M, Abi-Dargham A, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Three compartment modeling of [123I]IBF binding to dopamine D2 receptors in human. Soc Neurosci Abstr 1993;19:1064. 14. Laruelle M, Bradberry CW, Al-Tikriti M, Abi-Dargham A, van Dyck CH, Malison RT, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: DAmphetamine induced displacement of [123I]IBF equilibrium binding: A SPECT paradigm to evaluate dopamine release. Scientific Abstracts, 32nd Annual Meeting of the American College of Neuropsychopharmacology 1993. 15. van Dyck CH, Seibyl JP, Malison RT, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Age-related decline in dopamine transporter binding in human striatum with [123I]ß-CIT SPECT. J Nucl Med 1994;35(5):11P. 16. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblat W, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine induced dopamine release reduces the binding potential of [123I]IBF for dopamine D2/D3 receptors in humans. J Nucl Med 1994;35(5):84P. 17. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblat W, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine induced displacement of [I-123] IBF equilibrium binding – A SPECT paradigm to evaluate dopamine release. Schizophrenia Research 1994;11(2):170-171. 18. van Dyck CH, Seibyl JP, Malison RT, Wallace E, Laruelle M, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Age-related decline in dopamine transporter binding with [123I]ß-CIT SPECT. Soc Neurosci Abstr 1994;20:387. 19. Laruelle M, Al-Tikriti M, Abi-Dargham A, van Dyck CH, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine-induced reduction of dopamine D2 availability in primates: Comparison between [123I]IBF and [123I]IBZM. Soc Neurosci Abstr 1994;20:644. 20. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB: SPECT imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release. Scientific Abstracts, 33rd Annual Meeting of the American College of Neuropsychopharmacology 1994. 21. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, Price LH, Leckman JF, Innis RB: [123I]ß-CIT SPECT imaging in Tourette's disorder. American Psychiatric Association 148th Annual Meeting, New Research Program and Abstracts 1995. 22. Laruelle M, van Dyck CH, Abi-Dargham A, D'Souza D, Gil R, Erdos J, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Charney DS, Krystal J, Innis RB: 41 C. H. van Dyck, M.D. May 3, 2017 SPECT Imaging of dopamine release following amphetamine challenge in healthy subjects and in patients with schizophrenia. J Nucl Med 1995;36(5):10P. 23. Malison RT, Best S, Wallace EA, van Dyck CH, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Laruelle M, Seibyl J, McCance-Katz E, Price LH, Kosten TR, Innis RB: SPECT imaging of dopamine transporters in cocaine dependent and healthy control subjects with [123I]ß-CIT. J Nucl Med 1995;36(5):31P. 24. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Wisniewski G, Narayan M, Hoffer PB: Comparison of 99mTc-HMPAO and 99mTc-ECD cerebral SPECT images in Alzheimer's disease. J Nucl Med 1995;36(5):108P. 25. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Wisniewski G, Narayan M, Arnsten AFT, Hoffer PB: Effects of the acetylcholine releaser linopirdine on SPECT rCBF and cognitive function in Alzheimer's disease. J Nucl Med 1995;36(5):238P. 26. Narayan M, Lin CH, Robinson R, Cellar J, Hoffer PB, van Dyck CH: Comparison of 99mTc-HMPAO and 99mTc-ECD cerebral SPECT images in Alzheimer's disease. Am J Geriatr Psychiatry 1995;3:268-269. 27. Laruelle M, Abi-Dargham A, Gil R, van Dyck CH, et al: SPECT imaging of striatal dopamine release after amphetamine challenge in humans – relationship between subjective effects and dopamine release. Schizophrenia Research 1995;15(1-2):89-90. 28. Laruelle M, Abi-Dargham A, Gil R, van Dyck CH, Erdos J, D'Souza D, Rosenblatt W, Krueger S, McCance-Katz E, Bremner D, Abi-Saab D, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Krystal J, Charney DS, Innis RB: SPECT Imaging of synaptic dopamine activity in drug free schizophrenic patients. Soc Neurosci Abstr 1995;21:261. 29. van Dyck CH, Lin CH, Robinson R, Cellar J, Narayan M, Arnsten AFT, Hoffer PB: Effects of the acetylcholine releaser linopirdine on SPECT rCBF and cognitive function in Alzheimer's disease. Soc Neurosci Abstr 1995;21:1996. 30. Laruelle M, Abi-Dargham A, Gil R, van Dyck CH, Erdos J, D'Souza CD, Rosenblatt W, McCance-Katz E, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Krystal J, Charney DS, Innis RB: SPECT imaging of synaptic dopamine release in drug free schizophrenic patients. Scientific Abstracts, 34th Annual Meeting of the American College of Neuropsychopharmacology 1995. 31. Laruelle M, AbiDargham A, vanDyck CH, et al. Increased striatal dopamine release in drug free schizophrenic subjects. Biol Psychiatry 1996;39(7):208. 32. Laruelle M, AbiDargham A, Gil R, et al. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Research 1996;18 (2-3):XIID3. 42 C. H. van Dyck, M.D. May 3, 2017 33. Laruelle M, van Dyck CH, Abi-Dargham A, Rosenblatt W, Zoghbi SS, Baldwin RM, Hoffer PB, Charney DS, Innis RB: Age related decline in amphetamine-induced dopamine release measured with SPECT and [123I]IBZM in healthy subjects. J Nucl Med 1996;37(5):33P. 34. van Dyck CH, Seibyl JP, Laruelle M, Best S, Sheff K, Marek KL, Malison RT, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Aging effects with [123I]ß-CIT SPECT: analysis of gender, striatal subregion, and neuropsychological correlates. J Nucl Med 1996;37(5):272P. 35. van Dyck CH, Lin CH, Robinson R, Cellar J, Arnsten AFT, Hoffer PB: Effects of the acetylcholine-releaser linopirdine on SPECT regional cerebral blood flow and cognitive function in Alzheimer's disease. Am J Geriatr Psychiatry 1996;4(4):339-340. 36. van Dyck CH, Seibyl JP, Laruelle M, Sheff K, Marek KL, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Innis RB: Age-related decline in dopamine transporters with [123I]ß-CIT SPECT: analysis of gender, striatal subregion, and neuropsychological correlates. Soc Neurosci Abstr 1996;22:1201. 37. van Dyck CH, Seibyl JP, Laruelle M, Sheff K, Marek KL, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Innis RB: Age-related decline in dopamine transporters with [123I]ß-CIT SPECT: Analysis of gender, striatal subregion, and neuropsychological correlates. Scientific Abstracts, 35th Annual Meeting of the American College of Neuropsychopharmacology 1996, p.281. 38. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Seibyl JP, Baldwin RM, Krystal JH, Charney DS, Innis RB: SPECT imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Scientific Abstracts, 35th Annual Meeting of the American College of Neuropsychopharmacology 1996, p.26. 39. van Dyck CH, Seibyl JP, Fowler JS, Wong DF, Jeste DV: Imaging the aging dopamine system. Am J Geriatr Psychiatry 1997, abstract submitted. 40. van Dyck CH, Tan P-Z, Baldwin RM, Ramsby Q, Rich DA, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB: PET quantification of 5-HT2A/C receptors in the human brain: a constant infusion paradigm with [F-18]altanserin. J Nucl Med 1997;38(5):70P. 41. van Dyck CH, Gelernter JE, MacAvoy MG, Avery RA, Criden M, Okereke O, Seibyl JP, Hoffer PB: Increased parietal rCBF asymmetry in Alzheimer's disease lacking the apolipoprotein E 4 allele. J Nucl Med 1997;38(5):95P-96P. 42. Tan P-Z, Baldwin RM, van Dyck CH, Amici L, Al-Tikriti M, Roth B, Khan N, Fowler JS, Shea C, Soufer R, Charney DS, Innis RB: Identity and receptor binding of radiometabolites of the 5-HT2A/2C ligand [F-18]altanserin. J Nucl Med 1997;38(5):287P. 43 C. H. van Dyck, M.D. May 3, 2017 43. van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden MC, Okereke O, Seibyl JP, Hoffer PB: The absence of an apolipoprotein E 4 allele is associated with increased parietal rCBF asymmetry in Alzheimer's disease. Am J Geriatr Psychiatry 1997 abstract submitted. 44. Baldwin RM, Tan P-Z, van Dyck CH, Al-Tikriti M, Amici L, Roth B, Khan N, Soufer R, Charney DS, Innis RB: Radiometabolites of [18F]altanserin in rats and humans: 4-(p[18F]fluorobenzoyl)piperidine and [18F]altanserinol. J Labeled Compd Radiopharm 1997;40:SI 133-135. 45. Tan P-Z, Baldwin RM, Soufer R, van Dyck CH, Charney DS, Innis RB: Application of the deuterium isotope effect to enhance PET signal by impeding tracer metabolism: synthesis of deuterium and fluorine-18 dual-labeled altanserin and its nitro precursor. J Labeled Compd Radiopharm, 1997;40:SI 130-132. 46. Marek K, Innis R, Fussell B, et al. 1231 beta-CIT and SPECT: An imaging biomarker of Parkinson's disease progression. Neurology 1998;50(4):S40002. 47. van Dyck CH, Tan P-Z, Staley J, Baldwin RM, Al-Tikriti M, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB: PET quantification of 5-HT2A receptors: a constant infusion paradigm with [F-18]altanserin. J Nucl Med 1998;39(5):136P. 48. Tan P-Z, Soares J, Baldwin RM, van Dyck CH, Soufer R, Seibyl JP, Charney DS, Innis RB: H-2 and F-18 dual-labeled altanserin as a metabolically resistant PET ligand for serotonin-2A (5-HT2A) receptor. J Nucl Med 1998;39(5):21P. 49. Verhoeff NPLG, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, Baldwin RM, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, van Dyck CH, Krystal JH, Innis RB: Nicotine use effects on brain benzodiazepine receptors in schizophrenia measured by [123I]iomazenil SPECT. Problems of Drug Dependence 1999, Proceedings of the 61st Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. 50. van Dyck CH, Soares J, Tan P-Z, Staley J, Baldwin RM, Amici LA, Garg PK, Ng CK, Charney DS, Innis RB: Improved PET quantification of 5-HT2A receptors with [F18]deuteroaltanserin: a constant infusion paradigm. J Nucl Med 1999;40(5):273P. 51. Basso M, Yang J, Gelernter J, Half LM, MacAvoy MG, van Dyck CH: Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s disease. Soc Neurosci Abstr 1999;25:1058. 52. van Dyck CH, Basso M, Yang J, Half LM, MacAvoy MG, Varma P, Joel Gelernter J: Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s disease. Scientific Abstracts, 38th Annual Meeting of the American College of Neuropsychopharmacology 1999. 53. Tan P-Z, Soares JC, Staley JK, Seibyl JP, Baldwin RM, van Dyck CH, Al-Tikriti MS, Fu X, Charney DS, Innis RB: Utilization of deuterium isotope effect to enhance specific 44 C. H. van Dyck, M.D. May 3, 2017 brain uptake of [18F]altanserin, a 5-HT2A radiotracer for PET. J Labeled Compd Radiopharm 1999;42 Suppl. 1:66-67. 54. van Dyck CH: SPECT rCBF and MRI volumetric correlates of apolipoprotein E 4 in Alzheimer’s disease. Am J Geriatr Psychiatry 2000;8:57-58. 55. van Dyck CH, Basso M, Yang J, Half LM, MacAvoy MG, Varma P, Gelernter J: Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s disease. Proceedings of the 1st International Meeting, Alzheimer’s Imaging Consortium, July 8, 2000, Washington, D.C. 56. van Dyck CH, Basso M, Yang J, Half LM, MacAvoy MG, Varma P, Gelernter J: Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s disease. Neurobiol. Aging 2001;22(2):24. 57. van Dyck CH: Neuroimaging in Alzheimer’s disease: relevance for the development of therapeutic agents. CNS Drug Rev 2000;6(Supplement 1):26-27. 58. Lappalainen J, Kranzler H, Malison R, Price L, van Dyck CH, Rosenheck RA, Kramer J, Southwick S, Charney DS, Krystal JK, Gelernter J: Neuropeptide Y LEU7PRO polymorphism is associated with alcohol dependence in a large population sample from the U.S. Scientific Abstracts, 39th Annual Meeting of the American College of Neuropsychopharmacology 2000. 59. Kugaya A, Epperson N, van Dyck CH, Zoghbi, S, Hou Y, Fujita M, Staley J, Garg P, Seibyl J, Innis R: The effect of estrogen on brain serotonin2A receptors measured by PET in postmenopausal women. Soc Neurosci Abstr 2001. 60. van Dyck CH, Seibyl JP, Malison RT, Zoghbi SS, Baldwin RM, Innis RB: Agerelated decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10(2):62. 61. Staley JK, Mason G, Petrakis I, Zoghbi SS, Verhoeff NPLG, Seibyl JP, van Dyck CH, Innis RB, Baldwin R, Krystal JH. Assessment of cortical GABA function in acutely (< 7 days) detoxified alcohol dependent patients. J Nucl Med 2002;43(5):109P. 62. Fujita M, van Dyck CH, Ichise M, Zoghbi, SS, Tamagnan G, Bozkurt A, Seneca N, Mukhin AG, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP, Baldwin RM, Innis RB: Quantification of brain nicotinic acetylcholine receptors in humans using 123I-5-I-A-85380. J Nucl Med 2002;43(5):110P. 63. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Laruelle M, Staley JK, Baldwin RM, Innis RB, Gelernter J: 9-Repeat allele of the dopamine transporter gene is associated with increased dopamine transporter protein availability. J Nucl Med 2002;43(5):107P. 64. Staley JK, Mason G, Gottschalk C, Petrakis I, Zoghbi S, Verhoeff NP, Seibyl JP, van Dyck CH, Innis RB, Baldwin RM, Krystal JH: GABA system alterations in human 45 C. H. van Dyck, M.D. May 3, 2017 alcohol dependence: Insights from multimodal neurochemical imaging. Neuroscience Addiction International Conference, Mexico City, June 2002. 65. Fujita M, van Dyck CH, Ichise M, Zoghbi S, Tamagnan G, Bozkurt A, Seneca N, Mukhin A, Vaupel B, Horti A, Koren A, Khan S, Early M, Kimes A, London E, Seibyl J, Baldwin R, Innis R: Whole-body biodistribution, radiation-absorbed dose, and brain SPECT imaging with [I-123]5-I-A-85380 in healthy human subjects. Neuroimage 2002;11:S8. 66. Volkow ND, Swanson JM, Waldman E, Gainetdinov R, Spencer T, van Dyck CH: Dopamine transporters in ADHD: Increased, decreased, or unchanged? (Study Group) Scientific Abstracts, 41st Annual Meeting of the American College of Neuropsychopharmacology 2002. 67. Tariot P, Farlow M, Grossberg G, van Dyck CH, Gergel I, Graham S, Jin J: Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer’s disease. Alzheimer’s and Parkinson’s Diseases: New Perspectives, 6th International Conference, Seville Spain, May 8-12, 2003. 68. van Dyck, CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, Baldwin RM, Innis RB, Gelernter J: Central serotonin transporter availability measured with [123I]ß-CIT SPECT in relation to serotonin transporter genotype. J Nucl Med 2003;44(5):68P-69P. 69. Staley JK, Petrakis I, Gottschalk C, Ruff E, Frohlich E, Weinzimmer D, Seibyl JP, van Dyck CH, Baldwin RM, Krystal JH: [123I]Iomazenil SPECT imaging demonstrates no change in cortical benzodiazepine-GABA-A receptors in long term sober alcoholics. Annual Meeting for Research Society on Alcoholism, June-July 2003. 70. Staley JK, Petrakis I, Gottschalk C, Seibyl JP, Verhoeff P, Perry E, van Dyck CH, Baldwin RM, Krystal JH: Benzodiazepine receptor availability in recently abstinent alcohol dependent males: relationship to craving, withdrawal and smoking. Scientific Abstracts, 42nd Annual Meeting of the American College of Neuropsychopharmacology 2003. 71. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer's disease. Neurobiol Aging 2004;25 (Suppl. 2):S186. 72. Cummings JL, van Dyck C, Schmitt FA, et al. Functional and behavioral effects of memantine in Alzheimer's disease. Int J Neuropsychopharmacol 2004;7(Suppl. 1): S208. 73. Karlawish JH, James BD, Kim S, Knopman D, van Dyck CH, Marson D. Alzheimer's disease patient and caregiver attitudes about proxy informed consent. Neurobiol Aging 2004;25 (Suppl. 2):S345. 74. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer's disease. J Am Geriatr Soc 2004;52(4):S14. 46 C. H. van Dyck, M.D. May 3, 2017 75. van Dyck C, Ferris S, Graham S, et al. Response to memantine treatment in moderate to severe Alzheimer's disease. J Am Geriatr Soc 2004;52(4):S155. 76. Tariot PN, van Dyck CH, Schmitt FA, Graham SM, Olin JT, Jin J, Cummings JL. Functional and behavioral effects of memantine in Alzheimer’s disease. American Psychiatric Association Annual Meeting, New York, May 1-6, 2004. 77. Staley JK, van Dyck CH, Tamagnan G, Baldwin RM, Weinzimmer D, Riccardi P, Krystal JH, Seibyl JP. Test-retest reliability of [I-123]5-IA-85830 for SPECT imaging of ß2-nicotinic acetylcholine receptors. J Nucl Med 2004;45(5). 78. Staley JK, Krishnan-Sarin S, O'Malley S, Cosgrove KP, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, van Dyck CH. [I-123]5-IA-85830 SPECT imaging of ß2-nicotinic acetylcholine receptors in recently abstinent human tobacco smokers. Neuroimage 2004;22(Suppl. 2):T161. 79. Staley JK, van Dyck CH, Tamagnan G, Baldwin RM, Weinzimmer D, Riccardi P, Krystal JH, Seibyl JP. Reproducibility of equilibrium modeling of [I-123]5-IA-85830 SPECT measurements of ß2-nicotinic acetylcholine receptors. Neuroimage 2004;22(Suppl. 2):T195. 80. Staley JK, Krishnan-Sarin S, Kranztler E, Frohlich E, O’Malley S, Cosgrove K, Baldwin RM, Tamagnan G, Seibyl JP, Jatlow P, London ED, van Dyck CH. [I-123] 5-IA85380 SPECT imaging of ß2 nicotinic acetylcholine receptors in tobacco smokers. Soc Neurosci Abstr 2004. 81. van Dyck CH, Cummings J, Schmitt F, Graham SM, Olin JT, Jin J, Tariot PN. Functional and behavioral effects of memantine in Alzheimer's disease. European Neuropsychopharmacology 2004;14: S334-S335. 82. Schmitt FA, van Dyck CH, Feldman, H, Tariot PN, Peskind ER, Graham SM, Bell JM. Efficacy of memantine for cognitive deficits of mild to severe Alzheimer’s disease. Neuropsychopharmacology 2004:29(S1):S131. 83. Schmitt FA, van Dyck CH, Feldman, H, Tariot PN, Peskind ER, Resnick EM. Efficacy of memantine for cognitive deficits of mild to severe Alzheimer’s disease. American Association for Geriatric Psychiatry, San Diego CA, March 3-6, 2005. 84. Petersen, RC, Thal, LJ, Grundman M, Thomas RG, Bennett D, Doody R, Ferris S, Galasko D, Kaye J, Levey A, Pfeiffer E, van Dyck, CH: Donepezil And Vitamin E In Mild Cognitive Impairment. J Am Geriatr Soc 2005;53(4):S14. 85. Mitsis E, van Dyck CH, McKee S, Terlecki M, Haile CN, Brenner E, Tamagnan GT, Seibyl JP, Staley JK. Displacement of cortical and subcortical [123-I]5-IA-85380 uptake by cigarette smoke in human brain. J Nucl Med 2005;46(5). 47 C. H. van Dyck, M.D. May 3, 2017 86. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Donepezil and vitamin E in the progression of Mild Cognitive Impairment to Alzheimer’s disease: a hazard-ratio analysis. International Conference on AD Prevention, June 18, 2005, Washington, D.C. 87. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Operational criteria for patient recruitment in trials of Mild Cognitive Impairment. International Conference on AD Prevention, June 18, 2005, Washington, D.C. 88. Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ. Sex, apolipoprotein E 4 status, and hippocampal volume in mild cognitive impairment. International Conference on AD Prevention, June 18, 2005, Washington, D.C. 89. Schmitt FA, van Dyck CH, Feldman, H, Tariot PN, Peskind ER, Resnick EM. Efficacy of Memantine on cognition in mild to severe Alzheimer’s disease. American Psychiatric Association Institute on Psychiatric Services, October 5-9, 2005, San Diego, CA. 90. Mitsis EM, van Dyck CH, Krantzler E, McKee S, Perry E, Terlecki M, Brenner E, Jatlow P, Baldwin R, Tamagnan GD, Seibyl JP, Staley JK. (2005). Prolonged occupancy of nicotinic acetylcholine receptors by nicotine in human brain: A preliminary study. Annual Meeting of the Society for Research on Nicotine and Tobacco. 91. Staley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. Neuroimage 2006;31(Suppl. 2):T154-T154. 92. van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy MG, Ding YS, Gelernter J, Carson RE. Amyloid-ß burden and neuropsychological test performance in cognitively normal first-degree relatives at varying genetic risk for Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. Toronto 2010 April 9. 93. van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy MG, Ding YS, Gelernter J, Carson RE. Amyloid-ß burden and neuropsychological test performance in cognitively normal first-degree relatives at varying genetic risk for Alzheimer’s disease. Human Amyloid Imaging 2011 Meeting Abstracts. Miami Beach 2011 Jan 14. 94. van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy MG, Ding YS, Gelernter J, Carson RE. Amyloid-ß burden and neuropsychological test performance in cognitively normal first-degree relatives at varying genetic risk for Alzheimer’s disease. ICAD 2011. Paris 2011 Jul 16-21. 48 C. H. van Dyck, M.D. May 3, 2017 95. Salloway S, Porsteinsson AP, Sperling R, Keren R, van Dyck CH, Tariot PN, Gilman S, Crans G, Hernandez C, Quinn G, Bairu M, Cedarbaum JM, Pastrak A, Abushakra S for the ELND005-AD201 Investigators. Safety and Efficacy Results of a Phase 2 Randomized, Placebo-Controlled, Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer’s Disease. ICAD 2011. Paris 2011 Jul 16-21. 96. Porsteinsson AP, Sperling R, Salloway S, Keren R, van Dyck CH, Tariot PN, Arnold DL, Crans G, Hernandez C, Liang E, Bairu M, Cedarbaum JM, Pastrak A, Abushakra S for the ELND005-AD201 Investigators. Imaging and Cerebrospinal Fluid Biomarker Results of a Phase 2 Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer’s Disease. ICAD 2011. Paris 2011 Jul 16-21. 97. Salloway S, Berman RM, Coric V, Brody M, Andreasen N, van Dyck CH, Soininen H, Thein S, Shiovitz T, Kumar S, Pilcher G, Colby S, Rollin L, Feldman HH. Safety and Tolerability of BMS-708163 in a Phase 2 Study in Mild-to-Moderate Alzheimer’s Disease (AD). ICAD 2011. Paris 2011 Jul 16-21. 49